Vaxcyte (PCVX) Other financing activities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Other financing activities data on file, last reported at $9.0 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 49.31% year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $16.0 million, a 43.24% decrease from a year earlier, with the FY2025 full-year figure at $13.0 million, down 52.09% from the prior year.
• Other financing activities for Q1 2026 stood at $9.0 million, up from $3.4 million in the prior quarter.
• Over the last five years, Other financing activities for PCVX reached as high as $11.7 million in Q3 2024 and fell as low as $268000.0 in Q2 2022.
• Historically, Other financing activities has averaged $3.9 million across 5 years, with a median of $3.8 million in 2023.
• Across the five-year window, Other financing activities jumped 900.8% in 2024 and slumped 97.39% in 2025, its largest moves.
• Year by year, Other financing activities stood at $5.4 million in 2022, then declined by 23.67% to $4.1 million in 2023, then jumped by 45.77% to $6.0 million in 2024, then plunged by 42.93% to $3.4 million in 2025, then jumped by 164.48% to $9.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $9.0 million in Q1 2026, $3.4 million in Q4 2025, and $306000.0 in Q3 2025.